New analyses: GLP-1 receptor agonists reduce weight mainly by fat loss while preserving lean mass
- A new International Journal of Obesity meta-analysis found glucagon-like peptide-1 drugs cut weight mainly by reducing fat mass and belly fat, not muscle. - The review pooled 36 studies and 24 meta-analyzed trials; at three months, body weight fell about 9% as lean mass stayed largely preserved. - Clinicians already pair these drugs with protein and resistance training to protect muscle during obesity treatment. (nature.com)
Glucagon-like peptide-1 drugs work by helping people eat less and lose weight, and a new meta-analysis says most of that loss comes from fat. (nature.com) (pubmed.ncbi.nlm.nih.gov) The paper, published April 25 in the *International Journal of Obesity*, reviewed 36 studies in adults with overweight or obesity, with or without type 2 diabetes. Twenty-four studies were included in the quantitative meta-analysis. (nature.com) (pubmed.ncbi.nlm.nih.gov) Across those trials, body weight, body mass index, and waist circumference fell at 3, 6, and 12 months. At three months, mean body weight was down about 9%, with marked reductions in fat mass and visceral adipose tissue, the fat packed around internal organs. (nature.com) (pubmed.ncbi.nlm.nih.gov) At six months, average weight loss was about 5%, and the authors said lean mass remained largely preserved. At 12 months, weight loss persisted at around 4%, though results varied by drug, especially liraglutide. (nature.com) (pubmed.ncbi.nlm.nih.gov) That addresses a central worry around drugs such as semaglutide and liraglutide: that the number on the scale might be dropping because patients are losing too much muscle. The authors concluded that fat loss predominated while lean-body-mass reductions were modest. (nature.com) (pubmed.ncbi.nlm.nih.gov) The paper also points to a practical limit of the evidence. The included studies used different drugs, follow-up periods, and body-composition methods, so the authors said treatment should still be individualized. (nature.com) (pubmed.ncbi.nlm.nih.gov) Doctors are already testing that approach in clinic. A 200-person prospective cohort presented for the 2025 European Congress on Obesity reported minimal lean-muscle loss over six months in patients on semaglutide or tirzepatide who also received guidance on protein intake, exercise, and medication use. (eurekalert.org) (patientcareonline.com) Exercise guidance from the European Association for the Study of Obesity specifically recommends resistance training during weight loss to help preserve lean body mass. That fits the new review’s conclusion that nutrition and exercise should accompany drug treatment. (easo.org) (nature.com) Researchers are also studying effects beyond weight itself. A 2024 review in the *Journal of Clinical & Translational Endocrinology* said semaglutide may have anti-inflammatory effects, but it also said the exact mechanisms are not yet fully understood. (pmc.ncbi.nlm.nih.gov) The new paper does not say muscle loss never happens. It says the average pattern across published trials is better described as selective fat loss, with lean tissue relatively preserved when these drugs are used in obesity care. (nature.com) (pubmed.ncbi.nlm.nih.gov)
